Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects

17. října 2019 aktualizováno: GlaxoSmithKline

Gynaecological Follow-up of a Subset of 580299/008 Study Subjects

This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their last NCT00122681 study visit (Visit 10, Month 48).

This follow-up study will also be offered to subjects who were pregnant at their last NCT00122681 study visit (Visit 10, Month 48) so that no cervical sample could be collected at that visit.

The objectives & outcome measures of the primary phase (study 008/580299) are presented in a separate protocol posting (NCT00122681).

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Aktuální)

2022

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Austrálie
    • New South Wales
      • Westmead, New South Wales, Austrálie, 2145
        • GSK Investigational Site
    • Tasmania
      • Hobart, Tasmania, Austrálie
        • GSK Investigational Site
    • Victoria
      • Carlton, Victoria, Austrálie, 3053
        • GSK Investigational Site
      • Parkville, Victoria, Austrálie, 3052
        • GSK Investigational Site
    • Western Australia
      • Perth, Western Australia, Austrálie
        • GSK Investigational Site
  • Belgie
      • Brussels, Belgie, 1090
        • GSK Investigational Site
      • Edegem, Belgie, 2650
        • GSK Investigational Site
      • Leuven, Belgie, 3000
        • GSK Investigational Site
  • Brazílie
      • Campinas, Brazílie, 13083-970
        • GSK Investigational Site
      • Curitiba, Brazílie, 80060-150
        • GSK Investigational Site
    • Rio Grande Do Sul
      • Porto Alegre, Rio Grande Do Sul, Brazílie, 90035-003
        • GSK Investigational Site
  • Filipíny
      • Cavite, Filipíny
        • GSK Investigational Site
      • Laguna, Filipíny
        • GSK Investigational Site
      • Las Pinas City, Filipíny
        • GSK Investigational Site
      • Los Banos, Laguna, Filipíny, 4027
        • GSK Investigational Site
      • Makati City, Filipíny, 1231
        • GSK Investigational Site
      • Manila, Filipíny, 1004
        • GSK Investigational Site
  • Finsko
      • Helsinki, Finsko, 00610
        • GSK Investigational Site
      • Jyvaskyla, Finsko, 40100
        • GSK Investigational Site
      • Kotka, Finsko, 48100
        • GSK Investigational Site
      • Kouvola, Finsko, 45100
        • GSK Investigational Site
      • Kuopio, Finsko, 70100
        • GSK Investigational Site
      • Lahti, Finsko, 15110
        • GSK Investigational Site
      • Lappeenranta, Finsko, 53100
        • GSK Investigational Site
      • Mikkeli, Finsko, 50100
        • GSK Investigational Site
      • Oulu, Finsko, 90220
        • GSK Investigational Site
      • Pori, Finsko, 28100
        • GSK Investigational Site
      • Rauma, Finsko, 26100
        • GSK Investigational Site
      • Seinajoki, Finsko, 60100
        • GSK Investigational Site
      • Tampere, Finsko, 33100
        • GSK Investigational Site
      • Turku, Finsko, 20100
        • GSK Investigational Site
      • Vaasa, Finsko, 65100
        • GSK Investigational Site
  • Itálie
    • Emilia-Romagna
      • Modena, Emilia-Romagna, Itálie, 41100
        • GSK Investigational Site
  • Kanada
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2C8
        • GSK Investigational Site
    • British Columbia
      • Langley, British Columbia, Kanada, V3A 4H9
        • GSK Investigational Site
    • Nova Scotia
      • Truro, Nova Scotia, Kanada, B2N 1L2
        • GSK Investigational Site
    • Quebec
      • Beauport, Quebec, Kanada, G1E 7G9
        • GSK Investigational Site
      • Montreal, Quebec, Kanada, H2K 4L5
        • GSK Investigational Site
  • Německo
      • Berlin, Německo, 13086
        • GSK Investigational Site
      • Berlin, Německo, 13125
        • GSK Investigational Site
      • Hamburg, Německo, 20246
        • GSK Investigational Site
      • Hamburg, Německo, 22159
        • GSK Investigational Site
    • Baden-Wuerttemberg
      • Karlsruhe, Baden-Wuerttemberg, Německo, 76199
        • GSK Investigational Site
      • Ravensburg, Baden-Wuerttemberg, Německo, 88212
        • GSK Investigational Site
      • Rheinstetten, Baden-Wuerttemberg, Německo, 76287
        • GSK Investigational Site
    • Bayern
      • Muenchen, Bayern, Německo, 80637
        • GSK Investigational Site
      • Wuerzburg, Bayern, Německo, 97070
        • GSK Investigational Site
    • Hessen
      • Frankfurt, Hessen, Německo, 60439
        • GSK Investigational Site
    • Niedersachsen
      • Hannover, Niedersachsen, Německo, 30657
        • GSK Investigational Site
    • Rheinland-Pfalz
      • Mainz, Rheinland-Pfalz, Německo, 55116
        • GSK Investigational Site
    • Sachsen
      • Leipzig, Sachsen, Německo, 04279
        • GSK Investigational Site
    • Thueringen
      • Nordhausen, Thueringen, Německo, 99734
        • GSK Investigational Site
  • Spojené království
      • Aberdeen, Spojené království, AB25 7ZD
        • GSK Investigational Site
      • London, Spojené království, EC1M 6BQ
        • GSK Investigational Site
      • Manchester, Spojené království, M13 0JH
        • GSK Investigational Site
  • Spojené státy
    • Florida
      • Clearwater, Florida, Spojené státy, 33759
        • GSK Investigational Site
      • Miami, Florida, Spojené státy, 33136
        • GSK Investigational Site
    • Hawaii
      • Honolulu, Hawaii, Spojené státy, 96826
        • GSK Investigational Site
    • Iowa
      • Iowa City, Iowa, Spojené státy, 52242
        • GSK Investigational Site
    • Kansas
      • Wichita, Kansas, Spojené státy, 67207
        • GSK Investigational Site
    • Kentucky
      • Bardstown, Kentucky, Spojené státy, 40004
        • GSK Investigational Site
    • Nebraska
      • Omaha, Nebraska, Spojené státy, 68131
        • GSK Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, Spojené státy, 87131
        • GSK Investigational Site
    • New York
      • New York, New York, Spojené státy, 10029
        • GSK Investigational Site
    • North Carolina
      • Chapel Hill, North Carolina, Spojené státy, 27514
        • GSK Investigational Site
      • New Bern, North Carolina, Spojené státy, 28562
        • GSK Investigational Site
    • Oklahoma
      • Tulsa, Oklahoma, Spojené státy, 74105
        • GSK Investigational Site
    • Oregon
      • Portland, Oregon, Spojené státy, 97210
        • GSK Investigational Site
    • Pennsylvania
      • Erie, Pennsylvania, Spojené státy, 16508
        • GSK Investigational Site
      • Erie, Pennsylvania, Spojené státy, 16507
        • GSK Investigational Site
      • Philadelphia, Pennsylvania, Spojené státy, 19107
        • GSK Investigational Site
      • Pleasant Hills, Pennsylvania, Spojené státy, 15236
        • GSK Investigational Site
    • Washington
      • Wenatchee, Washington, Spojené státy, 98801
        • GSK Investigational Site
  • Tchaj-wan
      • Taipei, Tchaj-wan, 100
        • GSK Investigational Site
      • Taipei, Tchaj-wan, 112
        • GSK Investigational Site
      • Taipei, Tchaj-wan, 114
        • GSK Investigational Site
  • Thajsko
      • Bangkok, Thajsko, 10400
        • GSK Investigational Site
      • Bangkok, Thajsko, 10330
        • GSK Investigational Site
      • Bangkok, Thajsko, 10700
        • GSK Investigational Site
  • Španělsko
      • Barcelona, Španělsko, 08035
        • GSK Investigational Site
      • L'Hospitalet de Llobregat, Španělsko, 08907
        • GSK Investigational Site
      • Madrid, Španělsko, 28040
        • GSK Investigational Site
      • Móstoles/Madrid, Španělsko, 28935
        • GSK Investigational Site

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Written informed consent obtained from the subject prior to enrolment.
  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.

  • A subject previously enrolled in the study NCT00122681 and who fulfils either of the following criteria:

    • displayed normal cervical cytology but tested positive for oncogenic HPV infection at her last NCT00122681 study visit (Visit 10, Month 48).

or

- was pregnant at her last visit of the NCT00122681 study (Visit 10, Month 48) so that no cervical sample could be collected at that visit.

Exclusion Criteria:

  • A subject who displayed normal cervical cytology and who was negative for oncogenic HPV infection at her last NCT00122681 study visit (Visit 10, Month 48).
  • A subject who had a cervical lesion at her last NCT00122681 study visit (Visit 10, Month 48) or who had a cervical lesion that required treatment at the NCT00122681 exit colposcopy.
  • A subject for whom the cervical cytology results from the last NCT00122681 study visit (Visit 10, Month 48) were unavailable for reasons other than pregnancy.

If at the time of enrolment the subject experiences heavy bleeding (menstruation or other) or heavy vaginal discharge, or is pregnant, the pelvic exam cannot be performed. The subject's first study visit will be deferred until condition is resolved according to investigator's medical judgment.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Prevence
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Jiný: HPV-052 study subjects Group
The study group consisted of a subset of HPV-008 (NCT00122681) study subjects (15-25 years old at first study vaccination), who at their last study visit (Visit 10, Month 48) in HPV-008 (NCT00122681) study displayed normal cervical cytology, but were tested positive for oncogenic HPV infection, or were pregnant and hence no cervical sample could be collected at their HPV-008 (NCT00122681) concluding visit.
Jiný: Gynaecological follow-up
Subjects received a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years in this gynaecological follow-up study (HPV-052 EXT 008). No vaccine was administered in this extension study. Subjects received 3 doses of Cervarix/Havrix vaccine, administered intramuscularly, according to a 0, 1, 6-month vaccination schedule in the HPV-008 (NCT00122681) primary study.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of Subjects With HPV DNA in Cervical Samples by Hybrid Capture 2 Test (HCII)
Časové okno: At Months 12, 24, 36, 48

Subjects who presented oncogenic HPV DNA in cervical samples by HPV DNA testing. The presence of oncogenic HPV infection was determined by the Hybrid Capture 2 (HCII) test, which detects HPV DNA types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.

Missing = For some of the subjects whose result was indicated as quantity not sufficient (QNS).
At Months 12, 24, 36, 48
Number of Subjects With Colposcopy Referral and Colposcopy Adequacy
Časové okno: At Months 12, 24, 36, 48
Subjects with normal cervical cytology, who were found to be oncogenic HPV DNA positive in two subsequent tests, were referred to colposcopy. The result of the subjects' last HPV-008 study visit was taken into account at Visit 1. Subjects with a single cervical cytology reading of ≥ atypical squamous cells of undetermined significance (ASC-US) positive for oncogenic HPV DNA were referred for colposcopy. Subjects with a single cervical cytology reading of ≥ low grade squamous intraepithelial lesion (LSIL) were referred to colposcopy, irrespective of their oncogenic HPV DNA test result.
At Months 12, 24, 36, 48
Number of Subjects With Cytological Abnormalities in Cervical Samples by ThinPrep PapTest
Časové okno: At Months 12, 24, 36, 48

Subjects who presented normal, ASC-US (Atypical Squamous Cell of Undetermined Significance), LSIL (Low-grade Squamous Intraepithelial Lesions), HSIL (High-grade Squamous Intraepithelial Lesions), AGC (Atypical Glandular Cells), ASC-H (Atypical Squamous Cells cannot exclude HSIL) cervical cytology.

Cervical cytology examination was performed using the ThinPrep PapTest. Note: One subject may have presented with different cytology results at the yearly visit throughout the maximum 4-year follow-up period and therefore may be counted in more than one result category in the analysis.
At Months 12, 24, 36, 48
Number of Subjects With Cervical Biopsy Results at Month 12
Časové okno: At Month 12

Subjects with negative and positive cervical biopsy results for only CIN1, only CIN2, only CIN3, CIN1 and CIN2, CIN1 and CIN3, CIN2 and CIN3, CIN1 and CIN2 and CIN3, AIS, Invasive malignancy, other.

CIN = Cervical intraepithelial neoplasia. CIN1/CIN2/CIN3 = Cervical intraepithelial neoplasia grade 1/grade 2/grade 3.

Note: Only CIN1/Only CIN2/Only CIN3 categories contain the subject who has only CIN1/CIN2/CIN3, but not the combinations.
At Month 12
Number of Subjects With Cervical Biopsy Results at Month 24
Časové okno: At Month 24

Subjects with negative and positive cervical biopsy results for only CIN1, only CIN2, only CIN3, CIN1 and CIN2, CIN1 and CIN3, CIN2 and CIN3, CIN1 and CIN2 and CIN3, AIS, Invasive malignancy, other.

CIN = Cervical intraepithelial neoplasia. CIN1/CIN2/CIN3 = Cervical intraepithelial neoplasia grade 1/grade 2/grade 3.

Note: Only CIN1/Only CIN2/Only CIN3 categories contain the subject who has only CIN1/CIN2/CIN3, but not the combinations.
At Month 24
Number of Subjects With Cervical Biopsy Results at Month 36
Časové okno: At Month 36

Subjects with negative and positive cervical biopsy results for only CIN1, only CIN2, only CIN3, CIN1 and CIN2, CIN1 and CIN3, CIN2 and CIN3, CIN1 and CIN2 and CIN3, AIS, Invasive malignancy, other.

CIN = Cervical intraepithelial neoplasia. CIN1/CIN2/CIN3 = Cervical intraepithelial neoplasia grade 1/grade 2/grade 3.

Note: Only CIN1/Only CIN2/Only CIN3 categories contain the subject who has only CIN1/CIN2/CIN3, but not the combinations.
At Month 36
Number of Subjects With Cervical Biopsy Results at Month 48
Časové okno: At Month 48

Subjects with negative and positive cervical biopsy results for only CIN1, only CIN2, only CIN3, CIN1 and CIN2, CIN1 and CIN3, CIN2 and CIN3, CIN1 and CIN2 and CIN3, AIS, Invasive malignancy, other.

CIN = Cervical intraepithelial neoplasia. CIN1/CIN2/CIN3 = Cervical intraepithelial neoplasia grade 1/grade 2/grade 3.

Note: Only CIN1/Only CIN2/Only CIN3 categories contain the subject who has only CIN1/CIN2/CIN3, but not the combinations.
At Month 48
Number of Subjects With Treatment Referrals by Treatment Type at Month 12
Časové okno: At Month 12

If a high-grade lesion was detected, the subject was to be referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was to be handled according to local medical practice within the local health care system. The subject's participation in the study concluded after treatment.

The treatment types included the following: Loop excision of cervix, Loop cone of cervix, Cold knife cone of cervix, Laser excision, other.
At Month 12
Number of Subjects With Treatment Referrals by Treatment Type at Month 24
Časové okno: At Month 24

If a high-grade lesion was detected, the subject was to be referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was to be handled according to local medical practice within the local health care system. The subject's participation in the study concluded after treatment.

The treatment types included the following: Loop excision of cervix, Loop cone of cervix, Cold knife cone of cervix, Laser excision, other.
At Month 24
Number of Subjects With Treatment Referrals by Treatment Type at Month 36
Časové okno: At Month 36

If a high-grade lesion was detected, the subject was to be referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was to be handled according to local medical practice within the local health care system. The subject's participation in the study concluded after treatment.

The treatment types included the following: Loop excision of cervix, Loop cone of cervix, Cold knife cone of cervix, Laser excision, other.
At Month 36
Number of Subjects With Treatment Referrals by Treatment Type at Month 48
Časové okno: At Month 48

If a high-grade lesion was detected, the subject was to be referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was to be handled according to local medical practice within the local health care system. The subject's participation in the study concluded after treatment.

The treatment types included the following: Loop excision of cervix, Loop cone of cervix, Cold knife cone of cervix, Laser excision, other.
At Month 48
Number of Subjects With Adverse Events (AEs) or Serious Adverse Events (SAEs) Leading to Withdrawal
Časové okno: From Month 12 [i.e. 12 months after the last visit in HPV-008 (NCT00122681) primary study) up to Month 48 [i.e. 48 months after the last visit in HPV-008 (NCT00122681) primary study]
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
From Month 12 [i.e. 12 months after the last visit in HPV-008 (NCT00122681) primary study) up to Month 48 [i.e. 48 months after the last visit in HPV-008 (NCT00122681) primary study]
Number of Subjects With Any Fatal SAEs, With Any SAEs Assessed as Possibly Related to Study Participation or to a Concurrent GSK Medication.
Časové okno: From Month 12 [i.e. 12 months after the last visit in HPV-008 (NCT00122681) primary study) up to Month 48 [i.e. 48 months after the last visit in HPV-008 (NCT00122681) primary study]
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.
From Month 12 [i.e. 12 months after the last visit in HPV-008 (NCT00122681) primary study) up to Month 48 [i.e. 48 months after the last visit in HPV-008 (NCT00122681) primary study]

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

GlaxoSmithKline

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Užitečné odkazy

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

5. srpna 2009

Primární dokončení (Aktuální)

20. ledna 2014

Dokončení studie (Aktuální)

20. ledna 2014

Termíny zápisu do studia

První předloženo

2. července 2009

První předloženo, které splnilo kritéria kontroly kvality

9. července 2009

První zveřejněno (Odhad)

13. července 2009

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

29. října 2019

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. října 2019

Naposledy ověřeno

1. října 2019

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • 112024
  • 2008-008124-33 (Číslo EudraCT)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

IPD for this study is available via the Clinical Study Data Request site.

Časový rámec sdílení IPD

IPD is available via the Clinical Study Data Request site (click on the link provided below)

Kritéria přístupu pro sdílení IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY
  • MÍZA
  • ICF
  • CSR

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na Infekce, papilomavirus

Klinické studie na Gynaecological follow-up

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Estonia

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

Předplatit